KOSDAQBiotech & Pharma387570

Finemedix

₩5,060▲ 0.80%2026-11-18 close
Market Cap
₩28.5B
Turnover
₩21,920,135
Volume
4.4K
Shares out.
5.6M
PER
82.4×
PBR
1.4×
EPS
₩66
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Back in the Black: Overseas Growth and Profit Durability Are the Test

First-half 2026 revenue rose 43.7% and operating profit turned positive, but the 2025 annual losses and the thinner third-quarter profit mean earnings durability is still unconfirmed.

  1. 1

    First-half 2026 consolidated revenue was KRW 6.26 billion, up 43.7% year on year, and operating profit was KRW 39 million, turning positive from a year-earlier loss (company announcement of August 13, 2026).

  2. 2

    Annual revenue fell from KRW 10.2 billion in 2023 to KRW 9.52 billion in 2025, and operating results were in the red for two consecutive years from 2024 to 2025.

  3. 3

    Overseas revenue rose 51% to KRW 1.60 billion in the first half of 2026, but remains below the 50% share of total revenue that the company has set as its 2026 target.

  4. 4

    Quarterly revenue swung to KRW 2.23 billion in Q1 2026, KRW 4.03 billion in Q2 and KRW 2.62 billion in Q3, and Q3 operating profit of KRW 54.99 million was far below Q2.

  5. 5

    Operating cash flow turned to -KRW 2.63 billion in 2025, so the gap between reported results and cash generation is a point to monitor.

02

Business structure

Finemedix makes and supplies gastrointestinal endoscopy procedure instruments and was listed on KOSDAQ through the technology growth company special listing route on December 26, 2024.

Its main procedure areas are ESD (endoscopic submucosal dissection), EMR (endoscopic mucosal resection), EUS (endoscopic ultrasound) and ERCP (endoscopic retrograde cholangiopancreatography), and the company says it has commercialized 27 product types comprising 549 models supplied in 48 countries.

In Q1 2026, the product mix of KRW 2.23 billion in endoscopic procedure instrument revenue was led by Clear Grasp Snare at 22.34%, ClearCut Knife at 17.83% and Clear-Jet Injection Catheter at 12.49%, with therapeutic endoscopy accounting for 62.6% and diagnostic endoscopy for 9.36%.

Domestically the company sells mainly through direct sales to tertiary and large hospitals, and it says it supplies about 800 hospitals and clinics in total, including 22 tertiary hospitals such as Kyungpook National University Hospital, Asan Medical Center and Sinchon Severance.

Domestic revenue in the first half of 2026 was KRW 4.45 billion, up 38.2%, as equipment sales were added to the existing instrument business. The equipment business rests on distribution of endoscopes and ultrasound endoscopy systems from Sonoscape of China.

Overseas revenue was KRW 1.60 billion in the first half of 2026, up 51%, with first orders from new markets including the United States, Brazil, Japan and the Czech Republic alongside existing markets such as Russia, the United Kingdom and Malaysia.

In Japan the company supplies products under an ODM contract with Gadelius, while in the United States it focuses on supplying the ClearTip tissue-sampling instrument and building hospital references.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.2B-₩1.1B−48.9%
2025Q4₩3B-₩100M−4.4%
2026Q1₩2.2B-₩800M−33.7%
2026Q2₩4B₩800M19.6%
2026Q3₩2.6B₩54,992,0682.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩10.2B₩900M₩1.2B8.6%9.3%46.8%
2024₩10B-₩29,192,239-₩24,152,328−0.3%−0.1%29.4%
2025₩9.5B-₩2.6B-₩1.9B−27.1%−9.9%34.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue went from KRW 10.2 billion in 2023 to KRW 9.96 billion in 2024 (down 1.9% year on year) and KRW 9.52 billion in 2025 (down 4.4%), falling for two consecutive years from 2024 to 2025. 2023 was the largest revenue year in the 2023 to 2025 period and 2025 the smallest.

Operating profit of KRW 874 million in 2023 turned into an operating loss of KRW 29.19 million in 2024, and the 2025 operating loss widened to KRW 2.58 billion. Operating margin over the same period was 8.6%, -0.3% and -27.1%.

The company attributed the 2025 loss widening to delayed orders from major domestic and overseas customers, temporary costs from overseas certification transitions such as EU MDR, and higher headcount and marketing investment for global sales (preliminary results disclosed on February 20, 2026).

The filing attributes the slight decline in 2025 overseas revenue to delayed overseas orders. Profit attributable to owners of the parent was KRW 1.18 billion in 2023, a loss of KRW 24.15 million in 2024 and a loss of KRW 1.88 billion in 2025.

Net income including non-controlling interests was reported at the same levels for each year. Operating cash flow fell from KRW 1.38 billion in 2023 and KRW 171 million in 2024 to -KRW 2.63 billion in 2025.

The debt-to-equity ratio was 46.8% in 2023, 29.4% in 2024 and 34.3% in 2025, and total equity at the end of 2025 was KRW 19 billion.

Quarterly revenue moved from KRW 2.2 billion in Q3 2025 to KRW 2.97 billion in Q4 2025 (up 35.0% quarter on quarter), KRW 2.23 billion in Q1 2026 (down 24.8%), KRW 4.03 billion in Q2 2026 (up 80.6%) and KRW 2.62 billion in Q3 2026 (down 35.0% quarter on quarter, up 19.2% year on year).

In May 2026 the company said revenue from the Kmedihub education equipment installation project would be recognized in stages starting in the second quarter.

Operating results moved from an operating loss of KRW 1.07 billion in Q3 2025 and KRW 131 million in Q4 2025 (a narrower loss) to an operating loss of KRW 751 million in Q1 2026, then to operating profit of KRW 790 million in Q2 2026, before Q3 2026 operating profit of KRW 54.99 million fell 93.0% quarter on quarter.

Profit attributable to owners of the parent went from KRW 372 million in Q4 2025 to a loss of KRW 753 million in Q1 2026, a profit of KRW 777 million in Q2 and a loss of KRW 33.72 million in Q3 2026.

In Q3 2026 operating profit was positive while the attributable result was a net loss, so the gap between operating and final earnings was wide. Profit attributable to owners of the parent for the latest four quarters (Q4 2025 to Q3 2026) totaled KRW 363 million.

05

Industry analysis

Gastrointestinal endoscopy procedure instruments are consumable-type products whose use grows as therapeutic endoscopic procedures such as ESD and EMR expand.

The company says it succeeded in localizing gastrointestinal endoscopy procedure instruments in Korea for the first time and was founded in 2009 to break the monopoly structure held by overseas suppliers.

As of Q1 2026, the company said it maintains a domestic market share above 20% in the ClearCut Knife product line used for ESD. Overseas, the ClearTip EBUS-TBNA second generation received FDA approval in April 2026, and seven next-generation instrument models completed the transition to EU MDR certification.

On the cycle, the company describes 2025 as the year when overseas certification, licensing and headcount investment hit costs first, with 2026 the period in which revenue growth must show up as profit.

The equipment business depends on a domestic distribution agreement with Sonoscape, a Chinese endoscope equipment maker. The company also expects to benefit from rising health checkup demand in the second half of 2026, according to its May 2026 statements.

A news report citing one securities firm's analysis said overseas revenue fell in Q1 2026 on weaker Middle East sales, while the company said overseas revenue held at the prior-year level in the same quarter, so the sources read the same quarter differently.

Because many listed bio and pharma peers such as Samsung Biologics, Celltrion and Yuhan are centered on drugs and biologics, comparing Finemedix with sector-average metrics is less informative than reading it alongside the gastrointestinal endoscopy procedure market.

06

Outlook

The company has set a 2026 target of raising overseas revenue to 50% of total revenue. Overseas revenue in the first half of 2026 was KRW 1.60 billion against total revenue of KRW 6.26 billion, below half, so reaching the target requires a sharp step-up in overseas sales in the second half.

The company also set a medium-term target of KRW 3 billion to KRW 5 billion in annual revenue per country across five focus markets including Japan, the United States and Brazil.

In Japan it is preparing the full launch of the ClearCut Knife, which received product approval in early 2026, through marketing to local clinicians and network building.

In Europe, after completing the CE MDR transition for seven next-generation instrument models, it is expanding supplied products with country distribution partners and says it is also pursuing ODM and OEM business.

In Korea, the company plans to expand use of its core products at tertiary hospitals in the second half and to raise revenue per customer by selling equipment and instruments together.

In August 2026 it decided on a share buyback worth KRW 1 billion, which its CEO described as a reflection of management confidence in long-term corporate value. In April 2026 it received a BBB- credit rating from NICE D&B.

The next checkpoints are the trajectory of the overseas revenue share and whether equipment sales hold up quarter to quarter.

07

Valuation

PER
82.4×
PBR
1.4×
ROE
2.0%
EPS
₩66
BPS
₩3,774
Dividend per share
₩0

Earnings-based multiples are calculated on a thin earnings base, given the 2025 annual losses and profit attributable to owners of the parent of KRW 363 million over the latest four quarters, which is why they appear high.

When earnings are this small, the multiple swings sharply with one or two quarters of results, and the combination of a Q2 2026 profit and a Q3 2026 net loss keeps changing the reference point for interpretation.

The price-to-book ratio sits in a premium zone relative to book net assets, and because total equity of KRW 19 billion at the end of 2025 is entirely attributable to owners of the parent, the net asset comparison is straightforward.

The dividend yield is below the sector average, and the share buyback decided in August 2026 is the main shareholder return measure disclosed so far. The debt-to-equity ratio rose from 29.4% in 2024 to 34.3% in 2025 but remains below the 46.8% recorded in 2023.

How the valuation reads will depend on whether profitability holds over several quarters and whether operating cash flow recovers.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

First-half turnaround and top-line growth

First-half 2026 consolidated revenue was KRW 6.26 billion, up 43.7% year on year, and operating profit of KRW 39 million turned positive from a year-earlier loss. The company said selling, general and administrative expenses fell 2.1% year on year.

It attributes the result to domestic direct sales, equipment sales and first overseas orders working together, according to its August 13, 2026 announcement.

New overseas markets and certifications

Overseas revenue rose 51% to KRW 1.60 billion in the first half of 2026, with first orders from the United States, Brazil, Japan and the Czech Republic. The ClearCut Knife received Japanese product approval in early 2026, and seven next-generation instrument models completed EU MDR certification.

In the United States the second-generation ClearTip EBUS-TBNA received FDA approval in April 2026, widening the base for local supply.

Penetration of Korean tertiary hospitals

Sales at the top 10-odd hospitals in the Seoul metropolitan area rose 60% year on year, and direct sales in Daegu and Gyeongbuk rose nearly 24%. The company says it supplies about 800 hospitals and clinics, including 22 tertiary hospitals. As of Q1 2026, the company said its domestic share in the ESD-use ClearCut Knife product line is above 20%.

09

Bear factors

Loss widening in 2025

The 2025 operating loss widened to KRW 2.58 billion and the operating margin was -27.1%. The net loss attributable to owners of the parent was KRW 1.88 billion, and operating cash flow turned to -KRW 2.63 billion.

The company explained that certification and licensing costs and headcount and marketing investment were reflected in results first.

Volatile quarterly earnings

Operating profit fell from KRW 790 million in Q2 2026 to KRW 54.99 million in Q3, a 93.0% quarterly decline. Profit attributable to owners of the parent turned into a KRW 33.72 million net loss in Q3.

Over the latest four quarters the total was only KRW 363 million, so one or two quarters can change the overall picture significantly.

Distance from the overseas target

The company has set a 50% overseas revenue share target for 2026, but the first-half share remained below half. A news report citing one securities firm's analysis said Q1 2026 overseas sales fell on weaker Middle East demand, which conflicts with the company's own description. Overseas revenue also declined slightly in 2025 because of delayed orders.

10

Risk factors

Earnings volatility and equipment sales

The company said revenue from the Kmedihub education equipment project would be recognized in stages from the second quarter. Equipment revenue can vary widely by quarter depending on individual contracts.

Q3 2026 revenue of KRW 2.62 billion came in well below Q2's KRW 4.03 billion, so whether quarterly revenue can be sustained is still unproven.

Product and customer concentration

In Q1 2026 the top three products, Clear Grasp Snare at 22.34%, ClearCut Knife at 17.83% and Clear-Jet Injection Catheter at 12.49%, together accounted for more than half of instrument revenue. Domestic sales focus on tertiary hospitals, so changes in large-hospital adoption have an outsized effect. Overseas sales depend heavily on distribution partners such as Gadelius in Japan.

Certification and licensing timing and overseas orders

Overseas sales depend on country-by-country product licensing and certification timelines. In 2025, certification transition costs and delayed overseas orders weighed on results.

Reaching the overseas target requires repeat orders in new markets such as the United States and Japan, and a demand drop in specific regions such as the Middle East could also move quarterly results.

11

What to watch next

  1. Mid-February 2027 (approx.)

    Preliminary 2025 results were disclosed on February 20, 2026. Whether the 2026 annual preliminary results show a narrower operating loss or a turn to profit, and whether revenue exceeds the 2025 level of KRW 9.52 billion, are the points to check.

  2. End of March 2027

    This is the statutory filing deadline for the 2026 annual report. The DART filing fixes full-year 2026 revenue, operating margin and operating cash flow, and shows whether they reconcile with the quarterly totals.

  3. Mid-May 2027 (approx.)

    Q1 2026 results were disclosed on May 14, 2026. The points to check are whether Q1 2027 revenue exceeds the KRW 2.23 billion of Q1 2026 and whether the overseas share rises above the first-half level.

  4. Mid-August 2027 (approx.)

    The 2026 half-year report was filed on August 13, 2026. The 2027 half-year report will show progress toward the 50% overseas share target, whether equipment revenue is sustained and how the share buyback is being executed.

12

Overall view

Finemedix is a medical device company that is pursuing domestic direct sales to tertiary hospitals and an expansion of overseas approvals at the same time, built on its localization of gastrointestinal endoscopy procedure instruments.

Annual revenue has declined since 2023, and operating results were in the red for two consecutive years in 2024 and 2025, when certification, headcount and marketing costs were reflected in earnings.

In the first half of 2026 revenue rose 43.7% and operating profit of KRW 39 million turned positive, supported by domestic direct sales, equipment sales and first overseas orders.

On the other side, Q3 2026 operating profit of KRW 54.99 million fell well below Q2 and ended in a net loss attributable to owners of the parent, and profit attributable to owners over the latest four quarters totals only KRW 363 million.

The company's target of a 50% overseas revenue share is still above the first-half level, so the second half matters.

Bullish factors include revenue growth, the turn to profit, certifications and the share buyback, while bearish factors include quarterly earnings volatility, uneven equipment sales and uncertain timing of overseas orders.

The next checkpoints are the 2026 annual preliminary results around February 2027 and the 2026 annual report due by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. mt.co.kr
  2. hankyung.com
  3. dailian.co.kr
  4. digitaltoday.co.kr
  5. supple.kr
  6. sedaily.com
  7. pharm.edaily.co.kr
  8. news.nate.com
  9. view.asiae.co.kr
  10. kr.investing.com
  11. kr.investing.com
  12. v.daum.net
  13. sisa-news.com
  14. news.nate.com
  15. v.daum.net
  16. finemedix.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis